Jonathan Symonds Buys 1,500 Shares of GSK plc (LON:GSK) Stock

GSK plc (LON:GSK) insider Jonathan Symonds purchased 1,500 shares of the stock in a transaction on Friday, December 20th. The stock was acquired at an average price of GBX 1,315 ($16.48) per share, with a total value of £19,725 ($24,727.34).

Jonathan Symonds also recently made the following trade(s):

• On Wednesday, October 30th, Jonathan Symonds bought 7,150 shares of GSK stock. The stock was bought at an average cost of GBX 1,394 ($17.48) per share, for a total transaction of £99,671 ($124,947.98).

GSK Stock Performance

Shares of GSK opened at GBX 1,341.50 ($16.82) on Wednesday. GSK plc has a 52-week low of GBX 1,282.50 ($16.08) and a 52-week high of GBX 1,823.50 ($22.86). The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04. The firm has a market cap of £54.73 billion, a price-to-earnings ratio of 1,187.17, a PEG ratio of 1.24 and a beta of 0.31. The business’s 50 day moving average is GBX 1,384.87 and its two-hundred day moving average is GBX 1,504.20.

GSK Dividend Announcement

The company also recently declared a dividend, which will be paid on Thursday, January 9th. Stockholders of record on Thursday, November 14th will be issued a GBX 15 ($0.19) dividend. The ex-dividend date of this dividend is Thursday, November 14th. This represents a dividend yield of 1.03%. GSK’s dividend payout ratio (DPR) is 5,309.73%.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Shore Capital reaffirmed a “buy” rating on shares of GSK in a research note on Wednesday, August 28th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 1,850 ($23.19) price target on shares of GSK in a research report on Tuesday, September 3rd. Finally, Berenberg Bank cut their price objective on GSK from GBX 1,820 ($22.82) to GBX 1,600 ($20.06) and set a “buy” rating on the stock in a report on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, GSK has a consensus rating of “Moderate Buy” and a consensus target price of GBX 1,805.83 ($22.64).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.